BioRestorative Therapies Secures Patent Allowance for Innovation
BioRestorative Therapies, Inc. (NASDAQ: BRTX), renowned for its innovative work in regenerative medicine, proudly announces a recent milestone in its intellectual property journey. The Israel Patent Office has granted a Notice of Allowance for a new patent application—Israeli Patent Appl. No. 287557—that covers crucial elements of the Company's pioneering ThermoStem technology.
Important Aspects of the Patent
This patent marks the 14th international patent granted for BioRestorative's ThermoStem platform outside of the United States. The coverage includes innovative processes surrounding non-naturally occurring three-dimensional brown adipose derived stem cell (BADSC) aggregates. The application also encompasses a unique encapsulation system utilizing these BADSC aggregates and outlines a method for treating various disorders, which highlights the advanced therapeutic potential of the technology.
CEO's Perspective on the Patent Issuance
Lance Alstodt, BioRestorative's Chief Executive Officer, expressed his vision for the future of the company's stem cell therapies. "We believe that our ThermoStem-based BADSCs hold tremendous promise to deliver superior efficacy and better tolerability compared to GLP-1 drugs," Alstodt stated. He emphasized that this patent issuance is indicative of the Company's dedication to safeguarding its innovative endeavors and enhancing its commercial prospects, particularly in light of Israel's reputation as a leader in stem cell research.
Recent Developments in BioRestorative's Programs
In May 2024, BioRestorative unveiled an exciting new exosome-based biological program aimed at obesity management. This marks the next step in their development pipeline, which will involve initiating formal processes with the U.S. Food and Drug Administration (FDA) by filing a Drug Master File (DMF) for approval. In addition, discussions with a leading regenerative medicine company about potentially licensing BioRestorative’s off-the-shelf ThermoStem metabolic products are underway.
Exploring Core Clinical Development Programs
BioRestorative operates primarily through two clinical development streams: the treatment of disc/spine diseases and metabolic disorders. The company’s flagship therapy, BRTX-100, employs a cell therapy method derived from a patient’s own cultured mesenchymal stem cells taken from their bone marrow. The goal is to provide effective, non-surgical solutions to individuals suffering from painful lumbosacral disc disorders.
Diving Deeper into the Metabolic Program
The company’s Metabolic Program focuses on leveraging brown adipose derived stem cells (BADSC) to generate effective treatments for obesity and related metabolic issues. The potential role of brown adipose tissue (BAT) in caloric burning and glucose management is well-documented, offering hope for those struggling with similar conditions. Findings suggest that enhanced levels of BAT might lead to a healthier metabolic profile in individuals prone to obesity and diabetes.
The Promise of BioCosmeceuticals
Moreover, BioRestorative is actively expanding into the BioCosmeceuticals market, offering products formulated to utilize the principles of regenerative medicine for beauty and skincare. Their current proprietary biologic serum, designed to diminish fine lines, utilizes advanced cell-based secretome technologies. BioRestorative envisions an expansion in this field, potentially leading to more FDA-approved products that harness the power of their cutting-edge biological research.
Contact Information
For further inquiries, BioRestorative invites interested parties to reach out to:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
Frequently Asked Questions
What is the significance of the recent patent allowance for BioRestorative?
The recent patent allowance solidifies an important aspect of BioRestorative's ThermoStem technology, enhancing its competitive edge in regenerative medicine.
How does the ThermoStem program work?
ThermoStem utilizes brown adipose derived stem cells to help develop new treatments targeting obesity and metabolic disorders.
What are the core programs being developed by BioRestorative?
BioRestorative is focused on two main clinical programs: treatments for disc/spine disorders and those aimed at metabolic diseases.
How does BioRestorative engage with the FDA regarding its products?
BioRestorative plans to initiate the approval process with the FDA through formal submissions, including plans for a Drug Master File for its new therapeutic candidate.
What should investors know about BioRestorative's growth potential?
With its innovative approaches and recent developments in metabolic treatments and cosmetic applications, BioRestorative holds significant promise for future growth and investment opportunities.
